It's nearly impossible to find a marijuana stock that has performed well over the years; even a game-changing event like President Donald Trump's late 2025 executive order to reschedule the drug didn't move the needle. Many marijuana companies, including industry stalwart Canopy Growth (NASDAQ: CGC), have seen their share prices erode along with their fundamentals. If you still aim to invest in something smokable that produces a reliably strong passive income stream, consider ditching Canopy Growth and o ...

Canopy Growth (NASDAQ: CGC) is a high-risk investment. The stock has lost over 95% of its value since its initial public offering. There was material excitement around marijuana stocks and Canopy Growth a few years ago, but the company has not lived up to Wall Street's perhaps overzealous expectations. Now is probably not the time to jump aboard. Canopy Growth falls to $1 At one point in 2019, a share of Canopy Growth would have cost over $560 (after adjusting for reverse splits). Today, that same share ...

Core Viewpoint - Cannabis stocks have underperformed over the past five years, but recent positive regulatory changes in the U.S. may present long-term growth opportunities if the marijuana market expands significantly [1] Group 1: Canopy Growth - Canopy Growth is a leading player in the Canadian cannabis market with a diverse product portfolio, including dried cannabis flower, vapes, and edibles, and has a presence in multiple countries, including the U.S. [2] - Following President Trump's executive order to classify cannabis as a Schedule III substance, Canopy Growth may have expansion opportunities in the U.S. [3] - In Q3 2026, Canopy Growth reported net revenue of $54.62 million, a slight decrease of 0.3% year-over-year, but improved its net loss per share to $0.13 from $0.81 in the previous year [3] - If Canopy Growth can capitalize on U.S. opportunities and continue to reduce losses, it could yield strong returns [4] Group 2: Tilray Brands - Tilray Brands also has a comprehensive portfolio of cannabis products and operates in several countries, including the U.S., Germany, and Portugal, and has diversified into craft brewing and hemp-based products [5] - In Q2 of its 2026 fiscal year, Tilray reported net revenue of $217.5 million, a 3% year-over-year increase, while its net loss improved to $0.41 from $0.99 in the previous year [6] - Tilray is well-positioned to take advantage of emerging opportunities in the U.S. cannabis market, which could lead to significant share price increases if successful [6]

Core Viewpoint - Canopy Growth Corporation (NASDAQ:CGC) is undergoing significant financial restructuring to improve its balance sheet and extend debt maturities, while facing challenges in valuation and market conditions [1][3]. Group 1: Financial Adjustments - Alliance Global analyst Aaron Grey has reduced the price target for Canopy Growth Corporation from C$2.50 to C$1.80, maintaining a Neutral rating due to uncertainties regarding veteran reimbursement changes and potential gross margin pressures [1]. - The company has announced a recapitalization plan that includes securing a new US$150 million term loan due in 2031 to refinance existing debt and enhance working capital flexibility [3]. - Canopy Growth has also reached an agreement to exchange a portion of its 2029 convertible debentures for new 2031 debentures, cash, equity, and warrants, which aims to improve capital structure flexibility and provide multi-year liquidity visibility [3]. Group 2: Company Overview - Canopy Growth Corporation, founded in 2013 and headquartered in Smiths Falls, Ontario, is involved in the production and distribution of recreational and medical cannabis products across various markets [4].

Group 1 - Canopy Growth Corporation (NASDAQ:CGC) is recognized as one of the best cannabis stocks to invest in currently [1] - Alliance Global has reduced its price target for Canopy Growth from C$2.50 to C$1.80 while maintaining a Neutral rating, reflecting concerns over veteran reimbursement changes and gross margin uncertainties [2] - The company reported a fiscal third-quarter loss of C$0.18 per share, an improvement from a loss of C$1.11 per share in the same quarter last year, with revenue increasing from C$86.24 million to C$90.39 million [3] Group 2 - Canopy Growth operates in multiple segments including Canada Cannabis, International Markets Cannabis, Storz and Bickel, This Works, and Other [4] - The management highlighted ongoing efforts to enhance operational execution and mentioned the acquisition of MTL Cannabis as a strategic move to strengthen the company's platform [3]

Company Overview - Canopy Growth has seen its stock value decline by over 40% in the past year, with its market cap dropping from approximately $1.5 billion to just under $400 million, and it has not reported a profitable quarter since Q2 2021 [1] - Green Thumb Industries is positioned as a profitable alternative in the cannabis sector, on track for its sixth consecutive year of positive earnings per share [2] Financial Performance - Canopy Growth reported a revenue of $90.4 billion in its fiscal 2026 third quarter, marking a 5% year-over-year increase, but still incurred a net loss of $0.18 per share, which was a 49% reduction in loss compared to previous periods [4] - The company has reduced its net long-term debt by 25% to $225 million, although this was achieved by issuing new stock, leading to a 142% increase in the number of shares outstanding over the past year [5] Market Position and Strategy - Canopy Growth has operations in Canada, Germany, and Australia, and its acquisition of Acreage Holdings aims to establish a presence in the growing U.S. cannabis market [5] - Green Thumb Industries operates 108 dispensaries and 20 manufacturing facilities across 14 states, and is expected to benefit significantly if cannabis is reclassified as a Schedule III substance, which would allow for standard business deductions [6][7] Tax Implications - Currently, cannabis companies face limitations on business deductions due to marijuana being classified as a Schedule I drug, resulting in U.S. cannabis companies paying an additional $2.3 billion in taxes in 2024 [7] - Rescheduling cannabis could enable companies like Green Thumb to invest more in growth, enhancing their profitability [7]

Core Insights - Aurora Cannabis (ACB) reported strong third-quarter results for fiscal 2026, with adjusted EPS of 9 cents, up from 4 cents year-over-year, and sales increasing by 7% to approximately $68 million (~C$94 million) [1][10] Financial Performance - For the nine months of fiscal 2026, Aurora Cannabis achieved significant top-line growth, with medical cannabis sales rising about 20% year-over-year to C$211.5 million, representing nearly 75% of total revenues [3] - The adjusted EBITDA for the nine months ended September 2025 increased by 35% year-over-year to C$44.7 million, indicating strong operating leverage in the medical cannabis segment [6] Medical Cannabis Segment - The growth in the medical cannabis segment was driven by higher sales in international markets such as Australia, Germany, and Poland, as well as increased revenues from insurance-covered and self-paying patients in Canada [4] - Management expects annual global medical cannabis revenue to reach C$269-C$281 million in fiscal 2026, reflecting a year-over-year growth of 10-15% [8] Strategic Focus - Aurora Cannabis is reallocating resources towards its high-margin global medical cannabis business, prioritizing international markets for growth while exiting lower-return activities [7][11] - The company plans to exit select lower-margin consumer cannabis markets in Canada, which is expected to improve margins despite incurring near-term transition costs [12] Consumer Cannabis Business - The consumer cannabis segment is facing challenges due to price compression and intense competition in Canada's adult-use market, which has negatively impacted revenues and margins [9][10] - Management noted that the consumer segment incurs higher sales and marketing costs, prompting a strategic pullback to enhance overall gross margins [12] Competitive Landscape - Aurora Cannabis operates in a highly competitive market, contending with companies like Canopy Growth and Tilray Brands, which are also focusing on international expansion and cost efficiency [13] Stock Performance and Outlook - Despite improving fundamentals in the medical cannabis sector, Aurora Cannabis currently holds a Zacks Rank 4 (Sell), indicating it is not recommended for new investments [16][17] - The unchanged earnings estimates over the past 30 days suggest limited near-term upside potential for the stock [17]

Core Insights - Canopy Growth Corporation reported mixed results for Q3, with revenue exceeding estimates and a narrower loss, although per-share results fell short of expectations [2][3] Financial Performance - Net revenue for the quarter was C$74.5 million, roughly unchanged from the previous year and above the C$70.5 million consensus estimate [3] - The company reported a loss of C$0.18 per share, an improvement of approximately 84% year-over-year, but higher than the expected loss of C$0.08 per share [3] - Net loss narrowed by 49% year-over-year, while adjusted EBITDA loss decreased by 17%, attributed to stronger sales execution and reduced SG&A expenses [4] Revenue Breakdown - Cannabis net revenue increased by 4% to C$52 million [4] - Canadian medical cannabis revenue rose by 15% to C$23 million, driven by growth in insured patients and larger order sizes [4] - Canadian adult-use revenue increased by 8% to C$23 million, supported by growth in infused pre-rolls and new all-in-one vape products [4] - International cannabis revenue declined by 31% year-over-year due to supply chain challenges in Europe, but increased by 22% sequentially as shipments improved [5] Cost Management - Consolidated gross margin decreased to 29% from 32% a year ago, reflecting lower international cannabis sales and changes in product mix [6] - Selling, general, and administrative expenses fell on an adjusted basis due to headcount reductions and lower third-party costs [6] - The company achieved C$29 million in annualized cost savings since March 2025 and continues to seek additional efficiencies [6] Strategic Developments - The acquisition of MTL Cannabis is on track to close in the current quarter, expected to strengthen the company's global cannabis platform [7] - CEO Luc Mongeau noted that the third quarter reflects improving fundamentals and a more focused operating model, particularly in Canada [7] - Following the report, shares of Canopy Growth increased by 1.9% [8]

Core Viewpoint - Canopy Growth has experienced a significant decline in stock value, losing over 99% and currently trading around $1, indicating that it may not be an attractive investment despite its low price [1] Financial Performance - Canopy Growth's revenue has been inconsistent, with a slight increase in net revenue of 6% year-over-year to CA$66.7 million ($49.3 million) in Q2 of fiscal year 2026 [3] - The company's net loss per share improved to CA$0.01 ($0.0074) compared to a loss of CA$1.48 ($1.09) in the same period last year [3] Industry Challenges - The cannabis industry faces structural problems, including significant regulatory oversight, intense competition, and illegal sales channels that undermine legal businesses [4] - The recent reclassification of cannabis from Schedule I to Schedule III in the U.S. may provide some benefits, such as easier access to banking and tax deductions, but it does not address Canopy Growth's specific challenges, especially given its struggles in the Canadian market since legalization in 2018 [5]

Core Viewpoint - Canopy Growth Corporation (CGC) is expected to report its third-quarter fiscal 2026 results on February 6, with a projected revenue of $50.6 million and a loss per share of 3 cents, indicating a significant increase in losses compared to the previous year [1][2][9]. Financial Performance - In the last reported quarter, CGC posted a loss per share of 1 cent, which was 90.9% better than the Zacks Consensus Estimate [1]. - The Zacks Consensus Estimate for fiscal third-quarter revenues is $50.6 million, reflecting a decrease of 5.3% from the same quarter last year [2]. - The loss per share estimate for the fiscal third quarter has remained constant at 3 cents over the past 30 days [3]. Market Segments - Canopy's cannabis operations encompass both recreational and medical markets, with previous quarter results showing growth in cannabis revenues driven by adult-use and medical cannabis segments in Canada [4]. - Adult-use revenue growth in Canada may have been supported by strong consumer demand for infused pre-roll joints (PRJ) and the launch of All-In-One (AIO) vape products [5]. - Medical cannabis sales in Canada likely benefited from increased insured patient enrollments, larger average order sizes, and an expanded product portfolio under the Spectrum Therapeutics brand [5]. International Operations - International cannabis revenues are under pressure due to ongoing supply-chain and execution challenges in Europe, similar to trends from the previous quarter [6]. - The company has initiated a turnaround strategy focusing on operational oversight and transitioning back to internally produced Canadian GMP flower, which appears to be positively influencing performance [6]. Strategic Initiatives - During the quarter, CGC launched several strategic initiatives, including the Claybourne Gassers range of AIO vaporizers and expanded the Spectrum Therapeutics portfolio in Australia with new softgel capsule offerings [8]. - The company also entered into an agreement to acquire all issued and outstanding common shares of MTL Cannabis Corp., indicating a focus on portfolio optimization and market consolidation [10].